• Home
  • About Us
  • Blog

Pulmonary Hypertension RN

  • What is Pulmonary Hypertension?
    • What is Pulmonary Hypertension?
    • Pulmonary Hypertension Symptoms
    • Types of Pulmonary Hypertension
    • Causes of Pulmonary Hypertension
    • PH vs. PAH
    • Diastolic Heart Failure vs. PAH
    • WHO Group 3 Pulmonary Hypertension, IPF & COPD
    • Pulmonary Veno-Occlusive Disease
    • Hereditary Hemorrhagic Telangiectasia (HHT)
      • Hereditary Hemorrhagic Telangiectasia (HHT) Treatment
    • Functional Classification of Pulmonary Hypertension
    • Congenital Heart Disease
      • Eisenmenger’s Syndrome
      • Update on Management of PAH-CHD
      • Congenital Heart Disease & Sleep Apnea
      • Complex Congenital Heart Disease
      • Atrial Septal Defect and Pulmonary Arterial Hypertension
    • Pediatric Pulmonary Arterial Hypertension
    • Sickle Cell and Pulmonary Hypertension
    • Stimulant Associated Pulmonary Arterial Hypertension
    • Porto-Pulmonary Syndrome
    • Research, Life Expectancy & Prognosis for PH
  • Diagnosing & Monitoring PAH
    • Pulmonary Arterial Hypertension Diagnosis
    • How Am I Doing? Assessing Your PAH.
    • Blood Tests
    • Cardiopulmonary Exercise Test (CPET)
    • CT (Computed Tomography) Scan
    • Echocardiogram: An Overview
    • Echocardiogram: A Detailed Look
    • Pulmonary Function Tests (PFTs)
    • Right Heart Catheterization
    • Six Minute Walk
    • Ventilation Perfusion Scan (VQ Scan)
    • CTEPH
      • CTEPH: WHO Group 4 Pulmonary Hypertension
      • PTE (Pulmonary Thromboendarterectomy) Surgery
      • Adempas used to Treat PAH and CTEPH
  • PAH Treatment
    • Pulmonary Hypertension Centers
    • Pulmonary Hypertension Treatments
    • Continuously Infused Therapies Used to Treat PH
    • Prostanoids for Treatment of PH
    • Adcirca and Revatio Used to Treat Pulmonary Arterial Hypertension (PAH)
    • Adempas used to Treat PAH and CTEPH
    • Tracleer, Letairis, and Opsumit Treatments
    • Oxygen Therapy for Pulmonary Hypertension
    • Salt and Water Restrictions
    • Exercise & PAH
    • Diuretics
    • Blood Thinners
    • Getting the Most Out of PAH Therapy
      • Letairis
      • Opsumit
      • Sildenafil (Revatio)
  • Research
  • FAQ’s
    • Implanted Remodulin Pump, Right Heart Catheterization, PAH & Pregnancy
    • Oral Treatments, Care Centers & Hole in Heart
    • FAQ’s: Altitude, Cold & Allergy Medications
    • FAQ’s: Psoriasis, Idiopathic PAH, Contraceptives & PAH
    • FAQ’s: Causes of Pulmonary Hypertension, Symptom Frequency & Care Centers
    • FAQ: PAH Experts, Pregnancy, Mild PAH & Vacationing
    • FAQ’s: CTEPH, Blood Clots, Corrective Surgery & PAH Care Centers
    • FAQ’s: VQ Scans & PAH Curable?
    • FAQ’s: Mild Pulmonary Hypertension?
    • FAQ’s: Boating, Swimming & Eating with PAH
    • FAQ’s: Borderline Pulmonary Hypertension, Hand Swelling, Children with PAH, Costs

Oral trepsostinil (Remodulin) approved by FDA

December 21, 2013 By Dr. Jeremy Feldman

Update on PAH TreatmentsAfter more than seven years of development and clinical trials, United Therapeutics received approval from the FDA on 12/20/2013 for their oral version of treprostinil (Remodulin).  The new drug will be called Orenitram.  Orenitram has had a bumpy course with three major trials completed and reported and only one of them positive.  The manufacturer has several ongoing studies to determine how to best use this medication.  In the positive study, Orenitram was compared to placebo in untreated patients.  Orenitram improved exercise capacity at the end of 16 weeks.

What does this mean for patients?

First, a new treatment option is always good news.  However, this medication will be very complicated to use properly.  It may be dosed two or three times daily with more recent studies using the three times daily dosing regimen.  In patients who have never been exposed to Remodulin, the medication has a substantial side effect burden.  Even at low doses, patients experience nausea, vomiting, headache, diarrhea, abdominal cramps, flushing and muscle aches.  The medication is started at a very low dose and then gradually increased over time.  In order to benefit from the medication, the dose must be increased.  When you look at the three completed studies, patients that achieved a dose of 4mg twice (or three times) daily by the end of 16 weeks had much better results.

One very exciting way of using Orenitram is in patients that have been on continuous Remodulin (IV or Subcutaneously) and have had a good response.  There is an ongoing study that is looking at switching such patients.

How will I use Orenitram?

Even though this medication showed very mild efficacy as single agent therapy in PAH patients not treated with other medications, I don’t think this is the optimal patient population.  I think that in patients that are doing very well but have more room to improve this medication may well have a role.  I am very excited about the prospect of being able to switch some patients from intravenous/subcutaneous Remodulin to the pill form.

Be careful!

Just being on a low dose of this medication is not enough.  If you and your doctor are not able to increase the dose over time then you may not benefit at all from this medication.  Over time we will learn more precisely what the dosing targets should be.  My read of the published literature suggests that at least 4mg three times daily is the absolute minimum dose that should be targeted by the end of six months and that by the end of the first year, perhaps 5-6 mg three times daily.

Filed Under: Blog, Home Page, Living with PAH, Pulmonary Hypertension Treatments

PAH Life Expectancy

PAH Research

Research, Life Expectancy & Prognosis for PH

Major Developments in Pulmonary Hypertension Affecting Prognosis 1.     Approval of

Where to Get Treatment?

CCCs for PAH

Pulmonary Hypertension Centers

Where to get treatment for pulmonary hypertension? Pulmonary arterial hypertension is a

Popular Posts

News about PAH

Combination Therapy for PAH Approved by FDA

By Dr. Jeremy Feldman

For the first time, the FDA has approved the use of two medications as initial therapy for pulmonary arterial

PAH couple

FAQ’s: Psoriasis, Idiopathic PAH, Contraceptives & Pulmonary Hypertension

By Dr. Jeremy Feldman

Is Psoriasis associated with pulmonary arterial hypertension? Psoriasis is an autoimmune skin disorder characterized by

good news in pah

 

Disclaimer

Recent Blog Posts

  • In Memoriam:  Greg Ahearn, MD June 16, 2024
  • Sotatercept (Winrevair) Approved! June 1, 2024
  • Disappointing News for Rodatristat Ethyl October 11, 2023

Categories

Archives